Sol-Gel Technologies (SLGL) Other Non Operating Income (2021 - 2023)
Sol-Gel Technologies (SLGL) posted quarterly Other Non Operating Income of $41000.0 for Q4 2023, up 192.86% quarter-over-quarter from $14000.0 in Q3 2023.
Sol-Gel Technologies (SLGL) Other Non Operating Income (2021 - 2023) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Other Non Operating Income for 2 consecutive years, with $41000.0 the latest figure, recorded in Q4 2023.
- In Q4 2023, Other Non Operating Income changed N/A year-over-year to $41000.0; the TTM figure through Dec 2023 stood at $579000.0 (changed N/A YoY), while the FY2023 annual figure was $55000.0, changed N/A from the prior year.
- Other Non Operating Income climbed to $41000.0 in Q4 2023 per SLGL's latest filing, from $14000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $554000.0 in Q3 2021 and bottomed at -$30000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Sol-Gel Technologies | 240.26 Mn | 230.12 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 41,000.00 |
| Sep 30, 2023 | 14,000.00 |
| Dec 31, 2021 | -30,000.00 |
| Sep 30, 2021 | 554,000.00 |